OOS Investigations 2026: Find True Root Cause and Stop Endless Retesting

Overview

Conducting Out-of-Specification (OOS) Investigations is a focused, 60-minute webinar designed to help quality, laboratory, and manufacturing teams properly investigate test results that fall outside approved specifications.

Out-of-specification results are one of the most common and highly scrutinized compliance issues in regulated industries. When improperly handled, they can lead to rejected batches, regulatory warning letters, costly recalls, and threats to patient safety. This webinar clarifies the expectations, breaks down the investigation process step-by-step, and teaches participants how to implement science-based, defensible decisions.

The training begins with foundational regulatory elements. Participants are introduced to key FDA, MHRA, WHO, and ICH expectations, emphasizing that an OOS event is not automatically a failure, nor should it be dismissed without evidence. The discussion highlights the differences between Out-of-Specification (OOS), Out-of-Trend (OOT), and invalid test results, ensuring attendees understand how to classify results appropriately before taking action.

Next, the session explores the three phases of OOS investigations. Phase I focuses on the laboratory investigation: verifying the analytical method, reviewing calculations and sample preparation, checking instrument performance, and assessing analyst competency. Attendees learn how to investigate within the lab without "testing into compliance," avoiding invalid retesting or retesting without justification.

Phase II expands beyond the laboratory when no clear lab-based root cause is found. Participants learn how to evaluate potential manufacturing issues, raw material quality, equipment malfunctions, environmental conditions, and process deviations. A strong emphasis is placed on identifying assignable versus non-assignable causes, using data to determine whether the result represents a true product failure. This section also covers how to determine the scope of an investigation, including whether additional lots, in-process material, stability samples, or distributed product require assessment.

The webinar then transitions into documentation and data interpretation requirements. Participants learn how to create clear, concise, and defendable OOS reports that include hypotheses, evidence, investigation actions, conclusions, and CAPA. Trending also plays an important role small, recurring signals often reveal systemic weaknesses that should not be overlooked during investigations.

Finally, the training addresses CAPA effectiveness, batch disposition decision-making, and integrating OOS management within the quality system. Attendees learn how to link investigation outcomes to corrective and preventive actions, determine when retraining or method revalidation is necessary, and establish criteria for batch release or rejection. The session concludes with best-practice checklists, common investigation errors, and simplified tools to support day-to-day application. Participants leave with not only a clear regulatory understanding, but also a practical framework for managing OOS investigations correctly and efficiently.

Why should you Attend

Professionals should attend Conducting Out-of-Specification (OOS) Investigations because handling OOS results incorrectly is one of the fastest ways for a company to receive regulatory citations, experience costly batch failures, or lose credibility with customers and regulatory auditors. OOS events are unavoidable, but poorly investigated OOS events are preventable. This webinar shows exactly how to manage them in a way that is scientifically sound, compliant with regulations, and defensible during inspections.

Participants will learn how to distinguish between true product failures and laboratory errors, ensuring that decisions are based on evidence rather than assumptions. The session provides a clear roadmap for executing investigations in a phased manner, beginning in the laboratory and expanding into manufacturing only when needed. This approach not only supports compliance but also saves time, labor, and resources.

The webinar also delivers practical tools for writing investigation reports that withstand regulatory scrutiny, explaining how to document hypotheses, testing rationales, conclusions, and CAPA in a way that auditors expect. It highlights common industry mistakes such as "testing into compliance" or ignoring minor trends so participants can avoid them immediately. Anyone involved in laboratory testing, quality systems, batch disposition, or manufacturing support will gain skills that protect both patients and the organization’s bottom line.

Areas Covered in the Session

• Introduction and Regulatory Context (5 minutes)
  
  • Definition of Out-of-Specification results
  • FDA and global regulatory expectations (21 CFR, MHRA, WHO)
  • Distinction between OOS, Out-of-Trend (OOT), and invalid results
  • Why effective investigations protect product quality and patient safety
• OOS Investigation Phases & Decision Framework (10 minutes)
  
  • Phase I: Laboratory investigation
  • Phase II: Full-scale investigation (beyond the lab)
  • Phase III: Impact assessment and corrective action
  • When an OOS result triggers a recall, batch rejection, or re-testing
  • Establishing investigation roles and responsibilities
• Phase I: Laboratory Investigation Requirements (10 minutes)
  
  • Confirm analytical method suitability and instrument performance
  • Verify sample handling, preparation, and dilution calculations
  • Evaluate analyst training and technique
  • Assess reference standards, reagents, and system suitability
  • Avoiding "testing into compliance" and invalid retesting practices
• Phase II: Full-Scale Investigation (10 minutes)
  
  • When to expand beyond the laboratory
  • Identifying root causes beyond testing: manufacturing, equipment, raw materials, environment
  • Evaluating manufacturing records, batch history, and deviations
  • Determining the scope of impacted lots, stability studies, and market product
  • Using risk-based justification for additional testing
• Data Interprétation & Documentation Expectations (10 minutes)
  
  • Proper documentation elements: hypothesis, evidence, conclusions
  • Trending: identifying recurring issues and weak signals
  • Distinguish assignable vs. non-assignable cause
  • When and how to use re-sampling and re-testing
  • Report structure: legally defensible and scientifically sound findings
• CAPA, Batch Disposition, and Lifecycle Management (10 minutes)
  
  • CAPA development based on root cause conclusions
  • Requirements for revalidation, retraining, or method remediation
  • Decision criteria for batch release or rejection
  • Preventing recurrence through continuous improvement
  • Integrating OOS investigations into QMS oversight and audits
• Q&A and Key Takeaways (5 minutes)
  
  • Best practice checklist for OOS investigations
  • Common mistakes and how to avoid them
  • Tools and templates available for implementation

Who Will Benefit

• Quality Assurance
• Quality Control (QC Laboratory)
• Analytical Development
• Manufacturing/Operations
• Validation/Engineering
• Regulatory Affairs
• Technical Services/Process Engineering
• Batch Release/Disposition Teams
• Supplier/Raw Materials Quality Management
• Stability Program Management
• Contract Manufacturing/Testing Oversight (CMO/CRO Management)